- Home
- RADX vs BNR Comparison
RADX vs BNR Comparison
Compare RADX & BNR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RADX
- BNR
- Stock Information
- Founded
- RADX 2021
- BNR 2014
- Country
- RADX Australia
- BNR China
- Employees
- RADX N/A
- BNR N/A
- Industry
- RADX
- BNR Medical Specialities
- Sector
- RADX
- BNR Health Care
- Exchange
- RADX NYSE
- BNR Nasdaq
- Market Cap
- RADX 32.5M
- BNR 38.3M
- IPO Year
- RADX N/A
- BNR 2020
- Fundamental
- Price
- RADX $4.43
- BNR $4.68
- Analyst Decision
- RADX Strong Buy
- BNR
- Analyst Count
- RADX 2
- BNR 0
- Target Price
- RADX $13.50
- BNR N/A
- AVG Volume (30 Days)
- RADX 19.9K
- BNR 17.4K
- Earning Date
- RADX 02-26-2025
- BNR 08-21-2025
- Dividend Yield
- RADX N/A
- BNR N/A
- EPS Growth
- RADX N/A
- BNR N/A
- EPS
- RADX N/A
- BNR N/A
- Revenue
- RADX $204,609.00
- BNR $72,112,038.00
- Revenue This Year
- RADX N/A
- BNR $136.32
- Revenue Next Year
- RADX N/A
- BNR N/A
- P/E Ratio
- RADX N/A
- BNR N/A
- Revenue Growth
- RADX N/A
- BNR 0.53
- 52 Week Low
- RADX $3.50
- BNR $2.18
- 52 Week High
- RADX $50.82
- BNR $7.90
- Technical
- Relative Strength Index (RSI)
- RADX N/A
- BNR 69.57
- Support Level
- RADX N/A
- BNR $4.47
- Resistance Level
- RADX N/A
- BNR $4.96
- Average True Range (ATR)
- RADX 0.00
- BNR 0.25
- MACD
- RADX 0.00
- BNR 0.11
- Stochastic Oscillator
- RADX 0.00
- BNR 84.31
About RADX RADIOPHARM THERANOSTICS LIMITED SPON ADS EACH REP 300 ORD
Radiopharm Theranostics Ltd is an Australian based clinical-stage radiotherapeutics company which is targeting cancer. The company has a pipeline of around four licensed platform technologies, with diagnostic and therapeutic applications in both pre-clinical and clinical stages of development. The company is engaged in research, development and commercialization of health technologies.
About BNR Burning Rock Biotech Limited
Burning Rock Biotech Ltd is a cancer diagnostics company. It is a NGS-based cancer therapy selection company. Its cancer therapy selection platform is built upon advanced proprietary technologies, comprehensive portfolio of products and a two-pronged market-driven commercial infrastructure addressing both larger hospitals through company's in-hospital model and smaller hospitals through its central laboratory model. It had three operating segments, including Central laboratory business, In-hospital business and Pharma research and development services. It generates the majority of its revenue from Central laboratory business. Its products are Pan-HEME, OncoScreen-WES, brPROPHET, OncoScreen Plus, and others.